Frequency CSO Chris Loose will present a company overview at the upcoming H.C. Wainwright Global Investment Conference. The recorded presentation will be available 5/24 at 7am ET. bit.ly/3wCt45Y

Frequency is leading a new category of regenerative medicine – one that uses small molecules to "activate" a person's innate regenerative potential. Learn more about our science: bit.ly/3PosQHu

Today, Frequency shared its Q2 2022 financial results and recent business updates. bit.ly/3SCmtTi

Today, Frequency announced its participation in investor and medical conferences coming up in September. Read more: bit.ly/3KxTzQG

Frequency CEO David L. Lucchino will present a company overview at H.C. Wainwright Global Healthcare Conference today at 11am EDT. A live webcast and replay of the presentation can be found at investors.frequencytx.com

Frequency CEO David Lucchino will present a company overview at the Baird Healthcare Conference today at 12:50 pm EDT. A live webcast and a replay of the presentation can be accessed at bit.ly/3xlhfT8

Frequency Co-Founder Jeff Karp (Pronouns: he/him/his) spoke with Brigham Clinical & Research News about how insights from his research on stem cell regeneration in the gut led to our approach of activating cells in the inner ear that may help restore hearing. Read more: bit.ly/3Dzm9zw

The Frequency team enjoyed a great day at the annual Hearing Loss Association of America’s New England Walk4Hearing. Thrilled to be able to support HLAA and all of their essential programs! #HLAA #Walk4Hearing

Today, Frequency Therapeutics announced enrollment completion of its Phase 2b study of FX-322, the Company’s lead hearing restoration candidate for individuals with sensorineural hearing loss. Study readout anticipated in Q1 2023. To learn more: frequencytx.gcs-web.com/news-releases/…

We were excited to join with colleagues in Amsterdam for #ECTRIMS2022 and to see the important research driving future MS treatments for patients.

Frequency’s Co-founder and CSO Chris Loose spoke with Longevity Technology about our small molecule regenerative medicine approach that aims to activate the body’s ability to restore function and reverse degenerative diseases. Read more: longevity.technology/news/the-next-…

Today, Frequency shared its Q3 2022 financial results and recent business updates. Learn more: investors.frequencytx.com/news-releases/…

Frequency is proud to sponsor #VetsAid2022 and to support VetsAid's important work to raise funds for veterans organizations. #HearingLoss is one of the leading disabilities impacting veterans and we are thankful to Joe Walsh for his commitment to this community.

On Dec. 13, Frequency will host a virtual investor event with presentations from management and key opinion leaders, with a focus on its lead hearing restoration program, FX-322. To learn more: investors.frequencytx.com/news-releases/…

Frequency is pleased to announce that the first patient has been dosed in the Phase 1b study of FX-345, our second hearing restoration candidate for individuals with sensorineural hearing loss. For more information: investors.frequencytx.com/news-releases/…

Thrilled to announce the world-class neurologists and drug developers on our new Remyelination Clinical Advisory Board to help support our multiple sclerosis program – and that Nobel laureate, Dr. James Rothman, has joined our Regen Med Advisory Board. bit.ly/3BLDbc6

Frequency Chief Scientific Officer Dr. Christopher Loose, Ph.D., will participate on a panel discussion at the 43rd Annual Cowen Healthcare Conference on March 8th at 12:50 p.m. ET. A live webcast and a replay of the presentation can be accessed at investors.frequencytx.com.

This International Women’s Day, Frequency honors the women who are advancing science and developing treatments to improve the health of others.

Frequency Chief Scientific Officer Dr. Christopher Loose, Ph.D., will present a company overview at the 33rd Annual Oppenheimer (Virtual) Healthcare Conference on March 13th at 8:00 am ET. A live webcast and a replay of the presentation can be accessed at investors.frequencytx.com.

March is #MSawarenessmonth, a time to recognize patients, the broader MS community, and the need to continuously advance scientific discovery in order to one day develop potentially restorative therapeutics.